Skip to main content Skip to main navigation menu Skip to site footer

Liver function characteristics of COVID-19 patients with obesity at Dr. Soetomo Hospital: case series

  • Erwin Maulana Farmanda Putra ,
  • Ummi Maimunah ,


Background: Coronavirus disease 2019 (COVID-19) patients with obesity are more susceptible to liver injury. There is currently no published overview regarding COVID-19 patients with liver injury in Indonesia. Our study reported 7 cases of obese COVID-19 patients with an increase of serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT), followed by 5 of them developing severe symptoms of COVID-19 in isolation room of Dr. Soetomo Hospital Surabaya within June-December 2020.

Case Presentation: A total of 7 COVID-19 patients, by the average age 46.2±15.5 years, were obese. The mean body mass index (BMI) was 36,3±3,4 kg/m2. Five of them experienced serious symptoms. There were 3 patients (patient no. 2, 4, 7) who had normal SGOT level, while the rest had an increased SGOT level for <2x upper limit of normal (ULN) at admission. During treatment, SGOT level increased in 5 patients for 1-<3x ULN and normal in the rest of them (patient no. 2, 4). Meanwhile, the normal SGPT levels were shown in 3 patients (patient no. 2, 4, 7) and increased in 4 others at admission for 1-<4x ULN. All of them tended to have an increased SGPT level during treatment for 1-<5x ULN. However, since the increase of SGOT and/or SGPT for >3x ULN is defined as liver injury, it happened in 2 patients that occur since admission (patient no. 3) and during treatment (patient no. 5).

Conclusion: Obesity may impede the recovery of COVID-19 and manifest in the deterioration of liver function.


  1. Fahriani M, Ilmawan M, Fajar JK, Maliga HA, Frediansyah A, Masyeni S, et al. Persistence of long COVID symptoms in COVID-19 survivors worldwide and its potential pathogenesis - A systematic review and meta-analysis. Narra J [Internet]. 2021;1(2). Available from:
  2. Fajar JK, Ilmawan M, Mamada S, Mutiawati E, Husnah M, Yusuf H, et al. Global prevalence of persistent neuromuscular symptoms and the possible pathomechanisms in COVID-19 recovered individuals: A systematic review and meta-analysis. Narra J [Internet]. 2021;1(3). Available from:
  3. Lusida MAP, Salamah S, Jonatan M, Wiyogo IO, Asyari CH, Ali ND, et al. Prevalence of and risk factors for depression, anxiety, and stress in non-hospitalized asymptomatic and mild COVID-19 patients in East Java province, Indonesia. PLoS One [Internet]. 2022 Jul 7;17(7):e0270966–e0270966. Available from:
  4. Fahriani M, Anwar S, Yufika A, Bakhtiar B, Wardani E, Winardi W, et al. Disruption of childhood vaccination during the COVID-19 pandemic in Indonesia. Narra J [Internet]. 2021;1(1). Available from:
  5. Wagner AL, Rajamoorthy Y, Taib NM. Impact of economic disruptions and disease experiences on COVID-19 vaccination uptake in Asia: A study in Malaysia. Narra J [Internet]. 2021;1(2). Available from:
  6. Sarengat R, Islam MS, Ardhi MS. Correlation of neutrophil-to-lymphocyte ratio and clinical outcome of acute thrombotic stroke in patients with COVID-19. Narra J [Internet]. 2021;1(3). Available from:
  7. Dinia F, Trisnantoro L, Helmi M. Managing Human Resources for Surge Capacity in Referral Hospitals Based on WHO Hospital Readiness Checklist for Covid-19. Folia Medica Indones [Internet]. 2022;58(2):141–9. Available from:
  8. Sutadji JC, Widodo ADW, Indiastuti DN. Mortality Comparison of Using Anti Interleukin-6 Therapy and Using Standard Treatment in Severe Covid-19. Folia Medica Indones [Internet]. 2021;57(2):158. Available from:
  9. Sharun K, Tiwari R, Iqbal Yatoo M, Patel SK, Natesan S, Dhama J, et al. Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects. Expert Opin Biol Ther [Internet]. 2020;20(9):1033–46. Available from:
  10. Triyono EA, Seipalla F, Djaja N, Akbas AMI, Ar-Rahmah KA, Budiono PS, et al. Clinical characteristics of patients with COVID-19 admitted to the COVID-19 Emergency Field Hospital of Bangkalan, Indonesia. F1000Research [Internet]. 2022;11:414. Available from:
  11. Cai Q, Chen F, Wang T, Luo F, Liu X, Wu Q, et al. Obesity and COVID-19 Severity in a Designated Hospital in Shenzhen, China. Diabetes Care [Internet]. 2020;43(7):1392–8. Available from:
  12. Harapan H, Fajar JK, Supriono S, Soegiarto G, Wulandari L, Seratin F, et al. The prevalence, predictors and outcomes of acute liver injury among patients with COVID-19: A systematic review and meta-analysis. Rev Med Virol [Internet]. 2021/10/13. 2022 May;32(3):e2304–e2304. Available from:
  13. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet (London, England) [Internet]. 2020/01/30. 2020 Feb 15;395(10223):507–13. Available from:
  14. Hu X, Pan X, Zhou W, Gu X, Shen F, Yang B, et al. Clinical epidemiological analyses of overweight/obesity and abnormal liver function contributing to prolonged hospitalization in patients infected with COVID-19. Int J Obes (Lond) [Internet]. 2020/06/22. 2020 Aug;44(8):1784–9. Available from:
  15. Zheng KI, Gao F, Wang XB, Sun QF, Pan KH, Wang TY, et al. Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. Metabolism [Internet]. 2020/04/19. 2020 Jul;108:154244. Available from:
  16. Liu L, Qu H, Li JJ, Yang YW, Zeng QX, Gong YW, et al. Effectiveness of methylprednisolone therapy in patients with a high-risk common type of COVID-19 pneumonia: a retrospective cohort study. Clin Exp Med [Internet]. 2021/10/22. 2022 Aug;22(3):487–97. Available from:
  17. Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, Del Prato S. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. lancet Diabetes Endocrinol [Internet]. 2020/07/17. 2020 Sep;8(9):782–92. Available from:
  18. Petrakis D, Margină D, Tsarouhas K, Tekos F, Stan M, Nikitovic D, et al. Obesity ‑ a risk factor for increased COVID‑19 prevalence, severity and lethality (Review). Mol Med Rep [Internet]. 2020/05/05. 2020 Jul;22(1):9–19. Available from:
  19. Zahra Z, Ramadhani CT, Mamfaluti T, Pamungkas SR, Firdausa S. Association between depression and HbA1c levels in the elderly population with type 2 diabetes mellitus during COVID-19 pandemic. Narra J [Internet]. 2022;2(1). Available from:
  20. Bangash MN, Patel J, Parekh D. COVID-19 and the liver: little cause for concern. lancet Gastroenterol Hepatol [Internet]. 2020/03/20. 2020 Jun;5(6):529–30. Available from:
  21. Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver Int [Internet]. 2020/03/30. 2020 May;40(5):998–1004. Available from:
  22. Bansal R, Gubbi S, Muniyappa R. Metabolic Syndrome and COVID 19: Endocrine-Immune-Vascular Interactions Shapes Clinical Course. Endocrinology [Internet]. 2020 Oct 1;161(10):bqaa112. Available from:
  23. Ritter A, Kreis NN, Louwen F, Yuan J. Obesity and COVID-19: Molecular Mechanisms Linking Both Pandemics. Int J Mol Sci [Internet]. 2020 Aug 12;21(16):5793. Available from:
  24. Cardoso FS, Pereira R, Germano N. Liver injury in critically ill patients with COVID-19: a case series. Crit Care [Internet]. 2020 May 5;24(1):190. Available from:
  25. Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, et al. COVID-19: Abnormal liver function tests. J Hepatol [Internet]. 2020/04/13. 2020 Sep;73(3):566–74. Available from:
  26. Ji D, Qin E, Xu J, Zhang D, Cheng G, Wang Y, et al. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. J Hepatol [Internet]. 2020/04/08. 2020 Aug;73(2):451–3. Available from:
  27. Eslam M, George J. Reply to: correspondence regarding “A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.” J Hepatol [Internet]. 2020;73(6):1575. Available from:
  28. Sharma P, Kumar A. Metabolic dysfunction associated fatty liver disease increases risk of severe Covid-19. Diabetes Metab Syndr [Internet]. 2020/06/10. 2020;14(5):825–7. Available from:
  29. van der Poorten D, Milner KL, Hui J, Hodge A, Trenell MI, Kench JG, et al. Visceral fat: A key mediator of steatohepatitis in metabolic liver disease. Hepatology [Internet]. 2008;48(2):449–57. Available from:
  30. Tang H, Zhou L, Li X, Kinlaw AC, Yang JY, Moon AM, et al. Drug-induced liver injury associated with lopinavir-ritonavir in patients with COVID-19: a disproportionality analysis of U.S. food and drug administration adverse event reporting system (FAERS) data. Int J Clin Pharm [Internet]. 2021/07/30. 2021 Aug;43(4):1116–22. Available from:
  31. Mostafa EMA, Tawfik AM, Abd-Elrahman KM. Egyptian perspectives on potential risk of paracetamol/acetaminophen-induced toxicities: Lessons learnt during COVID-19 pandemic. Toxicol reports [Internet]. 2022/03/29. 2022;9:541–8. Available from:
  32. Cao B, Wang Y, Wen D. A Trial of Lopinavir–Ritonavir in Covid-19. N Engl J Med [Internet]. 2020;382(21):e68. Available from:
  33. Zhao L, Pickering G. Paracetamol metabolism and related genetic differences. Drug Metab Rev [Internet]. 2010;43(1):41–52. Available from:

How to Cite

Putra, E. M. F., & Ummi Maimunah. (2022). Liver function characteristics of COVID-19 patients with obesity at Dr. Soetomo Hospital: case series. Bali Medical Journal, 11(3), 1795–1799.




Search Panel

Erwin Maulana Farmanda Putra
Google Scholar
BMJ Journal

Ummi Maimunah
Google Scholar
BMJ Journal